---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084309"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:41:15.553639+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia FDA lifts clinical hold on nex-z MAGNITUDE Phase 3 trial for ATTR-CM

## Summary
- FDA removed clinical hold on MAGNITUDE Phase 3 trial of nex-z for ATTR-CM after Grade 4 liver event on Oct 29, 2025.
- Mitigation measures include enhanced liver monitoring, short-term steroid guidance, and exclusion of certain liver abnormalities.
- For MAGNITUDE, added exclusion criteria for recent cardiovascular instability and ejection fraction <25%.
- MAGNITUDE-2 clinical hold for ATTRv-PN was resolved in January 2026; enrollment activities resuming.
- Amended ATM offering to up to $1.035B aggregate (from $750M); $635M sold, up to $400M additional shares remain.

## SEC filing metadata
- accession: 0001193125-26-084309
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/0001193125-26-084309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/d101756d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084309
- JSON: https://secwatch.observer/filing/0001193125-26-084309.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084309.txt

## Key facts
- Material Agreements
  Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at $1,035,316,650 (effective 2026-03-02).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: $1,035,316,650
  - Effective: 2026-03-02
  source text: On March 2, 2026, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $750,000,000 to $1,035,316,650.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/0001193125-26-084309-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.